RLS Global Introduces ChloraSolv to Veterinary Care Segment in Scandinavia

Global RLS the strategic goal is to expand its technical platform, buffered hypochlorite technology, to new indications, applications and geographies. Today, Global EPIRB may announce a strategic partnership with Swevet in the animal care segment for Sweden, Norway and Denmark.

During the second half of 2022, Global EPIRB examine alternatives for establishing distribution networks for the animal care segment in the rest of Europe and the Middle East.

Global EPIRB has established relationships with veterinary clinics within the major international animal care groups Anicura and Evidensiaclinics that are now ready to start using ChloraSolv in their treatment of difficult to heal wounds.

In collaboration with veterinarians, Global EPIRB evaluated ChloraSolv in the treatment of difficult to heal wounds in dogs, cats and horses. As the results are very positive, Global EPIRB is establishing a Scandinavian distribution network through an exclusive agreement with Swevet. Sweet is Sweden only full-line animal health wholesaler and works closely with veterinarians and other animal care clinic staff to support them in their business with knowledge and products.

“The animal segment is a new market and a new source of revenue for us,” says Karin FischerCEO, Global EPIRB. “But the principle of wound healing is similar for animals and for humans, so we are confident that ChloraSolv will bring great benefits in this segment.”

“Difficult-to-heal wounds that require prolonged treatments, increase the suffering for the animal, but also the costs for the animal owner. In the worst case, this can lead to amputation or having to put down the animal. ‘animal.”

Hard-to-heal wounds are a reality in animal health, as well as in human care. Injuries can be caused by everything from shards of glass and other sharp objects, to fights and bites and are also linked to diabetes. Healing can be made more difficult by bacteria and dirt from outside or by the animal licking the wound.

THIS IS CHLORASOLV
ChloraSolv is a debriding gel, based on unique hypochlorite technology, which is used with very good effect on leg ulcers and diabetic foot ulcers. The gel gently removes devitalized tissue and promotes the natural healing of wounds.¹ ChloraSolv does not damage healthy tissue and is well tolerated by the patient.

1. Eliasson B, Fagerdahl AM, Jönsson A, Apelqvist J. A single-arm, open-label, multicenter pilot investigation to assess the debriding effect of amino acid-buffered hypochlorite (ChloraSolv®) on chronic wounds covered with devitalized tissue during treatment six weeks. Wound Care Diary (Accepted for publication).

TRADING VENUE AND CERTIFIED ADVISOR:
Global RLS the shares have been listed on the Nasdaq First North Growth Market since the 17^e May 2017 and trading takes place under the abbreviated name RLS. The certified adviser is Redeye Aktiebolag, telephone: +46 8 121 576 90, e-mail: [email protected] During the period 2012-2017 the company was listed on Aktietorget.

FOR MORE INFORMATION PLEASE CONTACT:Karin FischerCEO, Global EPIRB
Email: [email protected]
Tel: +46 702 48 46 51

ON WORLD RLS:
RLS Global AB is a medical technology company within the life sciences. Based on the company’s unique hypochlorite platform, RLS develops and sells products for some of our most common diseases in wound and dental care. RLS has a portfolio of strong brands, including ChloraSolv® and Carisolv®.
The long-term vision of RLS is to be a leading research-driven platform in wound care. The ambition is to expand to new indications through new research and development projects in areas such as burns and dermatology. To maximize its market presence, RLS intends to work with partners to market its products globally. RLS is confident that the company’s technology platform and its unique features will help many patients around the world. Learn more at www.rls.global

https://news.cision.com/rls-global-ab/r/rls-global-introduces-chlorasolv-in-the-veterinary-care-segment-in-scandinavia,c3577470

(c) Decision 2022. All rights reserved., sources Press Releases – English